Emcure Pharmaceuticals has received approval for the reclassification of certain promoter group shareholdings to the ‘Public’ category. This reclassification, effective November 17, 2025, involves multiple individuals and entities within the promoter group. The move aligns with regulatory guidelines and does not affect the overall shareholding percentage, which remains at NIL for those reclassified.
Promoter Group Reclassification
Emcure Pharmaceuticals announced that it has received no-objection letters from both the National Stock Exchange of India Limited (NSE) and BSE for the reclassification of shareholding from the “Promoter and Promoter Group” category to the “Public” category, effective November 17, 2025.
Details of Reclassification
The reclassification involves several individuals and entities, all of whom will be moved from the Promoter Group to the Public category. The company clarified that post reclassification, the shareholding percentage for all those individuals and entities will be NIL. This is in accordance with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
List of Reclassified Parties
Jashvantlal Hiralal Shah
Pravina J. Shah
Jigar J. Shah
Manish J. Shah
Akhil Bharadwaj
Malti Bharadwaj
Aditi Shrivastava
Madan Mohan Thapar
Ramni Thapar
Bhavna Battu
Akanksha Eye Clinic & Nursing Home
Irrevocable Deed of Trust of Umakant Shah
Kaja Investments LLC
The RAMNI and MADAN THAPAR Revocable Living Trust
The company’s website, https://www.emcure.com/, will provide additional information regarding this announcement and related details.
Source: BSE
